Abstract 5112
Background
Most cancer patients are treated and followed up on an outpatient basis. A nursing led model of telephone care attention for cancer patients can be useful to improve the symptomatic control and the toxicity of the treatment. This model is being implemented in our hospital belonging to the Andorran Health Care Service. The specific aims of this study is to assess a nursing led model of telephone care attention for cancer patients in the course of treatment.
Methods
A descriptive prospective design has been used to analyze the telephone calls of cancer patients in treatment between outpatient appointments and the resolution capacity of oncology nurses. Telephone calls have been collected from October 2018 to March 2019 in a database. The variables analyzed using this database were: age, sex, type of tumor, type of treatment (oral or intravenous chemotherapy or immunotherapy), call reason and nursing resolution.
Results
49 telephone calls and 52 call reasons have been registered of 45 patients. On average, the patients were 58.1 (± 9.4) years old and 53% of them were male. Patients with colon and breast cancer were the most frequent, representing 20% and 16% respectively. 47% of patients were receiving intravenous chemotherapy, 36% oral chemotherapy and 18% immunotherapy. The call reasons were: 33% related to disease symptoms, 24 % related to toxicity, and 21 % related to treatment information and general issues. The most frequent reason for consultation was pain (23%) and the second was diarrhea (15%). Of the total telephone calls received, 92% were resolved by the nurse compared to 8% who required attention by a physician (p < 0.001).
Conclusions
Oncology nurse led model of telephone support for patients with cancer who attend outpatient treatment can improve symptomatic and toxicity management, reducing medical appointments and admissions to the Emergency Service.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Nostra Senyora de Meritxell.
Funding
Has not received any funding.
Disclosure
G. Simó: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. C. Royo: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Mahia: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. E. Baillés: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Echevarria: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. A. Berenguer: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell. S. Albiol: Full / Part-time employment: Hospìtal Nostra Senyora de Meritxell.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract